Shares of Ziopharm Oncology Inc. (NASDAQ:ZIOP) have been assigned a consensus recommendation of “Buy” from the seven research firms that are covering the company. Four investment analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $10.57.

ZIOP has been the topic of several recent research reports. Mizuho reaffirmed a “neutral” rating and issued a $5.00 price target (down previously from $7.00) on shares of Ziopharm Oncology in a report on Monday, July 18th. Griffin Securities reaffirmed a “buy” rating and issued a $21.00 price target on shares of Ziopharm Oncology in a report on Tuesday, June 7th. Wells Fargo & Co. raised shares of Ziopharm Oncology from an “underperform” rating to a “market perform” rating in a report on Wednesday, August 10th. Raymond James Financial Inc. initiated coverage on shares of Ziopharm Oncology in a report on Thursday, June 2nd. They issued a “market perform” rating on the stock. Finally, Zacks Investment Research raised shares of Ziopharm Oncology from a “hold” rating to a “buy” rating and set a $5.50 price target on the stock in a report on Wednesday, July 27th.

Ziopharm Oncology (NASDAQ:ZIOP) traded up 3.00% during mid-day trading on Tuesday, reaching $5.83. 1,969,417 shares of the company traded hands. The stock’s market capitalization is $760.79 million. The stock has a 50-day moving average of $5.32 and a 200 day moving average of $6.57. Ziopharm Oncology has a 52-week low of $4.45 and a 52-week high of $14.93.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/ziopharm-oncology-inc-nasdaqziop-given-average-rating-of-buy-by-analysts.html

Ziopharm Oncology (NASDAQ:ZIOP) last issued its earnings results on Tuesday, August 9th. The biotechnology company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.90. Ziopharm Oncology had a negative return on equity of 100.01% and a negative net margin of 2,292.26%. The company had revenue of $1.70 million for the quarter, compared to analyst estimates of $1.52 million. During the same quarter in the previous year, the company posted ($0.11) earnings per share. The company’s quarterly revenue was up 525.0% compared to the same quarter last year. Equities research analysts expect that Ziopharm Oncology will post ($1.34) earnings per share for the current year.

Several institutional investors have recently made changes to their positions in ZIOP. Fox Run Management L.L.C. purchased a new position in shares of Ziopharm Oncology during the second quarter valued at about $133,000. Stratos Wealth Partners LTD. purchased a new position in shares of Ziopharm Oncology during the first quarter valued at about $102,000. BlackRock Institutional Trust Company N.A. increased its position in shares of Ziopharm Oncology by 0.6% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 3,045,989 shares of the biotechnology company’s stock valued at $22,601,000 after buying an additional 17,982 shares during the last quarter. Commonwealth Equity Services Inc increased its position in shares of Ziopharm Oncology by 4.7% in the first quarter. Commonwealth Equity Services Inc now owns 46,575 shares of the biotechnology company’s stock valued at $346,000 after buying an additional 2,109 shares during the last quarter. Finally, TIAA CREF Investment Management LLC increased its position in shares of Ziopharm Oncology by 4.5% in the first quarter. TIAA CREF Investment Management LLC now owns 447,313 shares of the biotechnology company’s stock valued at $3,319,000 after buying an additional 19,211 shares during the last quarter. 44.95% of the stock is currently owned by institutional investors and hedge funds.

About Ziopharm Oncology

ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.

5 Day Chart for NASDAQ:ZIOP

Receive News & Ratings for Ziopharm Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ziopharm Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.